ArticleFrontiers in public health2026
Imaging features of primary type 2 diabetes patients with RR/MDR tuberculosis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To the best of our knowledge, imaging features of primary type 2 diabetes mellitus patients with rifampicin-resistant/multidrug-resistant tuberculosis (T2DM RR/MDR-TB) have not been reported in the literature to date. Hence this study investigated the imaging features of primary T2DM RR/MDR-TB patients. Methods: The clinical data and pulmonary CT findings of 87 primary T2DM RR/MDR-TB patients, 98 primary non-type 2 diabetes mellitus patients with rifampicin-resistant/multidrug-resistant tuberculosis (NT2DM RR/MDR-TB), 86 primary type 2 diabetes patients with drug-susceptible tuberculosis (T2DM DS-TB), and 93 primary pure drug-susceptible TB (DS-TB) patients without T2DM or RR/MDR-TB who were treated at Dalian Public Health Clinical Center from 2018 to 2023 were collected, and the clinical features and imaging differences among the four groups were compared using the chi-square test for categorical variables and the Kruskal-Wallis H test for ordinal or non-normally distributed continuous variables. Results: According to the results, among the four groups of patients, the NT2DM RR/MDR-TB patients were the youngest ( Conclusion: Imaging features, such as large solid nodules, patchy opacities, and particularly multiple cavities, are high-risk factors for T2DM in RR/MDR-TB patients. The presence of multiple cavities and extrapulmonary involvement increases with increasing blood glucose levels. Therefore, controlling blood glucose levels may reduce the risk and severity of T2DM RR/MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.